Patents by Inventor Christian Rohlff
Christian Rohlff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8652478Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.Type: GrantFiled: June 9, 2009Date of Patent: February 18, 2014Assignee: Oxford Biotherapeutics Ltd.Inventor: Christian Rohlff
-
Publication number: 20140024048Abstract: The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.Type: ApplicationFiled: August 9, 2013Publication date: January 23, 2014Applicant: OXFORD BIOTHERAPEUTICS, LTD.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20130273068Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Christian ROHLFF, Jonathan Alexander TERRETT
-
Publication number: 20130251723Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.Type: ApplicationFiled: October 3, 2011Publication date: September 26, 2013Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Patent number: 8540998Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: GrantFiled: December 24, 2008Date of Patent: September 24, 2013Assignee: Oxford Biotherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Patent number: 8535677Abstract: The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.Type: GrantFiled: December 1, 2010Date of Patent: September 17, 2013Assignee: Oxford Biotherapeutics, Ltd.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20130136689Abstract: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.Type: ApplicationFiled: December 13, 2012Publication date: May 30, 2013Inventors: Christian Rohlff, Alasdair Stamps
-
Patent number: 8420091Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.Type: GrantFiled: February 7, 2010Date of Patent: April 16, 2013Assignees: Oxford BioTherapeutics Ltd., Medarex, Inc.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20120282177Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120231004Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed.Type: ApplicationFiled: October 13, 2010Publication date: September 13, 2012Applicant: OXFORD BIOTHERAPEUTIC LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120114672Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.Type: ApplicationFiled: April 20, 2010Publication date: May 10, 2012Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Publication number: 20120058131Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.Type: ApplicationFiled: January 21, 2010Publication date: March 8, 2012Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Patent number: 8084034Abstract: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides.Type: GrantFiled: August 26, 2009Date of Patent: December 27, 2011Assignee: Oxford BioTherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20110229480Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer, for monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer treatment, and for drug development.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Publication number: 20110195026Abstract: The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.Type: ApplicationFiled: December 1, 2010Publication date: August 11, 2011Inventors: Christian ROHLFF, Jonathan Alexander TERRETT
-
Publication number: 20110195074Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.Type: ApplicationFiled: June 9, 2009Publication date: August 11, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Publication number: 20110110859Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.Type: ApplicationFiled: December 8, 2010Publication date: May 12, 2011Inventor: Christian Rohlff
-
Publication number: 20110027173Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: ApplicationFiled: December 24, 2008Publication date: February 3, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20100284918Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer and pancreatic cancer treatment, and for drug development.Type: ApplicationFiled: October 3, 2008Publication date: November 11, 2010Inventor: Christian Rohlff
-
Publication number: 20100284908Abstract: The present invention provides new polypeptides. Said polypeptides are of use in the screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer, in monitoring the effectiveness of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia), melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer and renal cell cancer treatment, and in drug development. Also provided are antibodies (and other affinity reagents such as Affibodies) which interact with or modulate the expression or activity of the polypeptides.Type: ApplicationFiled: August 26, 2009Publication date: November 11, 2010Inventors: Christian Rohlff, Alasdair Stamps